BioAdvance News

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing

By WebmasterSeptember 7, 2021November 1st, 2024No Comments

Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes SARS-CoV-2 Lambda and Delta Plus Variants in Pre-clinical Testing

– IMM-BCP-01 already shown to neutralize all other Centers for Disease Control (CDC) variants of concern in pre-clinical testing

Previous PostSyneos Health and Ride Health Partner to Improve Clinical Trial Recruitment and Retention
Next PostRenovacor Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange